Healthcare, Pharma & Life Sciences

Ascletis' Oral ASC50 Cuts Psoriasis Severity 48.9% in Phase I Trial

Image
Ascletis' Oral ASC50 Cuts Psoriasis Severity 48.9% in Phase I Trial

Hong Kong – – September 29, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) reported a 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) scores from a 28-day U.S. proof-of-concept trial of ASC50, an oral small molecule IL-17A inhibitor positioned as a needle-free alternative to injectable antibody therapies for plaque psoriasis.

Once-daily 200 mg dosing matched published efficacy benchmarks for injectable IL-17A antibody secukinumab

The randomized, double-blind, placebo-controlled Phase I study (NCT07024602) enrolled mild-to-moderate plaque psoriasis patients who received once-daily 200 mg oral ASC50 for 28 days. Ascletis said the PASI reduction was comparable to published secukinumab data, though the comparison was not conducted head-to-head.

UMG Becomes First German University Hospital to Deploy MDClone ADAMS

Image
UMG Becomes First German University Hospital to Deploy MDClone ADAMS

Göttingen, Germany – September 29, 2026 -- University Medical Center Göttingen (UMG) has become the first hospital in Germany and the European Union to deploy MDClone's ADAMS platform, layering advanced data utilization tools onto its existing UMG-MeDIC data integration center.

UMG becomes first EU adopter of internationally deployed ADAMS model

ADAMS is already operational at institutions including UChicago Medicine, Manchester University NHS Foundation Trust, and Sheba Medical Center. UMG's rollout marks the model's first entry into a German or EU university hospital, building directly on infrastructure established under Germany's national Medical Informatics Initiative (MII).

Blue Shield Commits $300,000 to Alameda Food Bank's Medicine Program

Image
Blue Shield Commits $300,000 to Alameda Food Bank's Medicine Program

Oakland – – September 29, 2026 -- Blue Shield of California has pledged a $300,000 multi-year investment to Alameda County Community Food Bank (ACCFB), marking the first deployment under the nonprofit insurer's new statewide Food as Health initiative.

Blue Shield becomes the first and largest corporate sponsor of ACCFB's Food as Medicine program

The funding will expand a program that delivers medically supportive food and nutrition education to eligible Medi-Cal members managing chronic conditions. The investment strengthens infrastructure, data collection, and evaluation systems needed to scale the model beyond its current reach.

Honest Lasers Launches Triple-Wavelength Swiss Diode Laser Globally

Image
Honest Lasers Launches Triple-Wavelength Swiss Diode Laser Globally

Roggwil, Switzerland – September 29, 2026 -- Honest Lasers has launched the Honest Pro, a Swiss-manufactured diode laser system combining three wavelengths and integrated contact cooling for aesthetic and medical clinics worldwide.

Three wavelengths operate within a single clinical platform

The Honest Pro integrates 755 nm, 808 nm, and 1064 nm wavelengths in one system, each targeting melanin at different tissue depths to allow practitioners to treat varied hair and skin types without switching devices. The system runs at a maximum pulse rate of 10 Hz, which Honest Lasers designed for stable fluence delivery across repeated treatments during a full clinic workday.

AHN Gets $1M Gift to Expand Alzheimer's, Memory Disorder Care

Image
AHN Gets $1M Gift to Expand Alzheimer's, Memory Disorder Care

Pittsburgh – September 29, 2026 -- Allegheny Health Network (AHN) has secured a $1 million commitment from Greg and Ellen Jordan to fund the Greg and Ellen Jordan Endowed Professorship for Alzheimer's Disease and Related Disorders within its Department of Neurology.

Jordan gift targets research, education and expanded memory disorder care

The endowment will fund clinical care, neuroscience research and support programming for patients with Alzheimer's disease, dementia and cognitive impairment. Greg Jordan is chairman of the Board of Directors of Highmark Health since 2025, sits on the board of MSA Safety, and serves as vice chairman of PNC after retiring as PNC's general counsel and chief administrative officer in 2024.

"We have each lost a parent to memory-related diseases, and we know that supporting AHN's research in this field is needed to continue to make progress on finding ways to deal with these challenges," Jordan said.

Viking Therapeutics Closes Upsized $575M Stock and Convertible Note Offering

Image
Viking Therapeutics Closes Upsized $575M Stock and Convertible Note Offering

San Diego – September 29, 2026 -- Viking Therapeutics, Inc. (Nasdaq: VKTX) has closed concurrent upsized public offerings totaling approximately $575.0 million in gross proceeds, funding to accelerate its late-stage obesity drug pipeline.

Viking raises $575 million through combined stock and convertible note sale

The clinical-stage biopharmaceutical company sold 9,035,714 shares of common stock at $35.00 per share, alongside $258.75 million in aggregate principal amount of 2.00% convertible senior notes due 2032. Both tranches were upsized after underwriters fully exercised their options, adding 1,178,571 shares to the equity offering and $33.75 million to the note offering.

TJP Acquires Evolution Consulting, Building End-to-End Life Sciences Platform

Image
TJP Acquires Evolution Consulting, Building End-to-End Life Sciences Platform

Conshohocken, Pa. – September 29, 2026 -- TJP, an independent agency focused on value and patient access for life sciences, has acquired Evolution Consulting & Research, a market research organization serving global pharmaceutical and biotech clients.

Acquisition completes TJP's end-to-end commercial platform for life sciences brands

The deal integrates Research, Strategy, Creative, Pull-Through, and Analytics into a single operating model. It follows TJP's earlier addition of FX2 Virtual, which brought Virtual Sales Professionals, Virtual Key Account Managers, reimbursement specialists, and omnichannel data analytics into the agency's portfolio.

Kye Pharmaceuticals Ranks No. 105 on Canada's Top Growing Companies List

Image
Kye Pharmaceuticals Ranks No. 105 on Canada's Top Growing Companies List

Mississauga, ON – September 29, 2026 -- Kye Pharmaceuticals ranked No. 105 on Report on Business magazine's 2026 list of Canada's Top Growing Companies, posting three-year revenue growth of 264%.

Kye secures second consecutive year on the Globe and Mail growth ranking

The Mississauga, Ontario-based specialty pharmaceutical company previously appeared on the 2025 edition of the list, marking its second straight year of recognition. The 2026 ranking included 376 companies in total, each qualifying through a voluntary application process and targeted revenue thresholds based on three-year growth performance.

Eden Radioisotopes Advances $1.4B N.M. Isotope Plant with Kiewit, State Backing

Image
Eden Radioisotopes Advances $1.4B N.M. Isotope Plant with Kiewit, State Backing

Albuquerque, N.M. – September 28, 2026 -- Eden Radioisotopes has secured New Mexico state economic support and locked in Kiewit Nuclear Solutions Co. as its engineering, procurement and construction partner for a planned $1.4 billion medical isotope production facility in Lea County, New Mexico.

New Mexico backs up to $1.4 billion investment through tax incentives

Economic Development New Mexico confirmed the state will support Eden's investment through the Job Training Incentive Program, high-wage and rural job tax credits, and LEDA GRT Share. The project is projected to create 205 jobs statewide and generate more than $1.5 billion in economic impact over 10 years.

Inner Circle Names Orthopaedic Healthcare CEO Patryk Kania Lifetime Member

Image
Inner Circle Names Orthopaedic Healthcare CEO Patryk Kania Lifetime Member

Houston – September 28, 2026 -- The Inner Circle has named Patryk Kania, a Chief Executive Officer in the orthopaedic healthcare sector, as a Lifetime Member in recognition of his leadership and industry contributions.

Kania brings 21 years of healthcare executive experience to orthopaedic services leadership

Kania has spent more than two decades in healthcare leadership roles, spanning both established enterprises and startup ventures. As CEO, he directs strategy for orthopaedic services organizations, with a focus on operational performance, growth initiatives, and patient-care outcomes.

Executive holds a master's degree from Simon Fraser University's Beedie School of Business

Kania's academic credentials include a master's degree from the Beedie School of Business at Simon Fraser University, which he credits as foundational to his approach to business strategy and organizational development in healthcare.